Tonix Pharmaceuticals Holding (TNXP) Income towards Parent Company: 2023-2025
Historic Income towards Parent Company for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -$31.8 million.
- Tonix Pharmaceuticals Holding's Income towards Parent Company fell 101.02% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.0 million, marking a year-over-year increase of 30.87%. This contributed to the annual value of -$136.7 million for FY2024, which is 39.20% down from last year.
- According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Income towards Parent Company is -$31.8 million, which was down 15.06% from -$27.7 million recorded in Q2 2025.
- Tonix Pharmaceuticals Holding's Income towards Parent Company's 5-year high stood at -$15.8 million during Q3 2024, with a 5-year trough of -$77.3 million in Q2 2024.
- Its 3-year average for Income towards Parent Company is -$29.8 million, with a median of -$27.3 million in 2023.
- The largest annual percentage gain for Tonix Pharmaceuticals Holding's Income towards Parent Company in the last 5 years was 64.21% (2025), contrasted with its biggest fall of 101.02% (2025).
- Over the past 3 years, Tonix Pharmaceuticals Holding's Income towards Parent Company (Quarterly) stood at -$27.3 million in 2023, then rose by 17.72% to -$22.5 million in 2024, then plummeted by 101.02% to -$31.8 million in 2025.
- Its Income towards Parent Company stands at -$31.8 million for Q3 2025, versus -$27.7 million for Q2 2025 and -$16.1 million for Q1 2025.